| Popis: |
Figure S1. Relapse-free survival curves (A) and overall survival curves (B) of patients stratified by 25(OH)D equal to or greater than 30 ng/mL. Figure S2. Kaplan-Meier curves of patients restricted only to adenocarcinoma, or both early stages (IA - IIB) and adenocarcinoma. Figure S3. Relapse-free survival curves (A) and overall survival curves (B) of patients stratified by SNPs of FokI. Mean (SD) of 25(OH)D in each genotype are as follows; FokI CC, 19.9 (6.2) ng/ml; CT, 21.8 (6.6) ng/ml; TT 21.4 (7.9) ng/ml. Figure S4. Relapse-free survival curves (A) and overall survival curves (B) of patients stratified by SNPs of BsmI. Mean (SD) of 25(OH)D in each genotype are as follows: BsmI AA, 15 (-) ng/ml; AG, 20.2 (6.4) ng/ml; GG 21.7 (6.8) ng/ml. Figure S6. Relapse-free survival curves (A) and overall survival curves (B) of patients stratified by SNPs of ApaI. Mean (SD) of 25(OH)D in each genotype are as follows: ApaI GG, 21.2 (7.2) ng/ml; GT, 21.4 (6.3) ng/ml; TT, 21.5 (7.7) ng/ml. Figure S7. Relapse-free survival curves (A) and overall survival curves (B) of patients stratified by SNPs of TaqI. Mean (SD) of 25(OH)D in each genotype are as follows: TaqI TT, 21.7 (6.7) ng/ml; TG, 20.4 (6.9) ng/ml; GG, - (-) ng/ml. Figure S8. Relapse-free survival curves (A) and overall survival curves (B) of patients stratified by SNPs of DBP1. Mean (SD) of 25(OH)D in each genotype are as follows: DBP1 TT, 21.3 (7.0) ng/ml; TG, 20.8 (6.0) ng/ml; GG, 23.6 (7.9) ng/ml. Figure S9. Relapse-free survival curves (A) and overall survival curves (B) of patients stratified by SNPs of DBP2. Mean (SD) of 25(OH)D in each genotype are as follows: DBP2 CC, 22.7 (6.6) ng/ml; CA, 20.0 (6.3) ng/ml; AA, 12.8 (1.5) ng/ml. |
